Breathing new life into mature medicines

Atnahs focuses on mature branded medicines globally. It wants to be the preferred acquirer for large cap or specialty pharma businesses choosing to divest its “mature”, “established” or “tail” off-patent branded medicines. Also, It develops line extensions (new formulations or new territories) to the medicines it acquires. Atnahs commits to continue the high-quality manufacturing and management of the medicines. At the same time, it aspires to breathe new life into the medicines, invest in them to make them stable and sustainable over the long-term.